Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLA | Q9Y4D2 | 4/20 | 0.52 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
| ▸ | CES1 | P23141 | 1/20 | 0.52 |
| ▸ | CTSS | P25774 | 9/20 | 0.50 |
| ▸ | CTSL | P07711 | 4/20 | 0.50 |
| ▸ | CTSB | P07858 | 4/20 | 0.50 |
| ▸ | CTSK | P43235 | 4/20 | 0.50 |
| ▸ | XDH | P47989 | 1/20 | 0.47 |
| ▸ | PRSS8 | Q16651 | 2/20 | 0.46 |
| ▸ | CMA1 | P23946 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6466909 | 0.91 | DAGLA (0.56) | DAGLAFAAHCES1CTSSCTSL | |
| SCHEMBL6466589 | 0.91 | DAGLA (0.56) | DAGLAFAAHCES1CTSSCTSL | |
| SCHEMBL6466058 | 0.85 | FAAH (0.49) | DAGLAFAAHCES1CTSSCTSL | |
| SCHEMBL6467558 | 0.84 | FAAH (0.46) | DAGLAFAAHCES1CTSSCTSL | |
| SCHEMBL6475526 | 0.84 | FAAH (0.46) | DAGLAFAAHCES1CTSSCTSL | |
| SCHEMBL6471948 | 0.83 | CTSS (0.50) | DAGLAFAAHCES1CTSSCTSL | |
| SCHEMBL6464884 | 0.83 | CTSS (0.49) | DAGLAFAAHCES1CTSSCTSL | |
| SCHEMBL6463429 | 0.83 | DAGLA (0.47) | DAGLAFAAHCES1CTSSCTSL | |
| SCHEMBL6463419 | 0.82 | CTSS (0.48) | DAGLAFAAHCES1CTSSCTSL | |
| SCHEMBL6465141 | 0.82 | CTSS (0.48) | DAGLAFAAHCES1CTSSCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1516877-A1 | Amine derivatives as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | DAGLA 2304/4885FAAH 479/4885CES1 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.